Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,444.25
(
0.58%
)
US TECH 100
28,731.60
(
1.56%
)
Dow Jones
49,693.20
(
-0.14%
)
Brent Oil
103.87
(
0.17%
)
Bitcoin
79,291.21
(
0.01%
)
News Focus
News Focus
Post# of 347009
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

biopharm

Send PM Follow Ignore
Followers 84
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

biopharm

Re: swg_tdr post# 278881

Wednesday, 11/16/2016 4:55:26 PM

Wednesday, November 16, 2016 4:55:26 PM

Post# of 347009
I hear that the cold front is moving in and the shorts will be removed

What does happen when all realize that it may not be 18 months to profitability and that Peregrine may have been "dramatically" cautious when releasing a timeline..

..and it is Sooner than expected

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote